Discussion in 'Other Health News and Research' started by Wally, May 25, 2015.
Read more: http://www.dailymail.co.uk/health/a...erve-cells-trigger-disease.html#ixzz3bCKFF25t
Thank you, Wally, for posting this.
I thought doubt had been thrown on this connection. Perhaps I am misremembering that. Still, if treatments are involved, I'd look hard at who is sponsoring the trials.
@duncan - Here is info. about the sponsor of this study.
Read more: http://www.dailymail.co.uk/health/a...erve-cells-trigger-disease.html#ixzz3bCi9Pm9U
People interested in Amyloidoisis as possible cause for ME/CFS may be interested in this update:
Merck's Alzheimer drug Verubecestat gets one step close, in Phase 111. Good BACE1 study results http://stm.sciencemag.org/content/8/363/363ra150.full
Quote: Merck’s drug significantly reduced levels of amyloid beta in the fluid surrounding the brain among the actual patients taking the drug. Dosing was short, with only 32 patients getting the drug daily for a week.
And Lilly also hot on the track with second phase 111 proposed:
Lilly was so committed to solanezumab — which also targets amyloid beta — that it mounted a new Phase III program after the last one failed. It also recently relegated one key measure on function to a secondary endpoint, flagging its lack of confidence on that score.
And most investigators in the field are moving upstream in the disease pathology, hoping to check the disease before it causes serious damage.
Despite billions spent on new trials over the past decade, though, the field has been afflicted by one setback after the next. Now Merck will take the most advanced study on BACE and help set the stage for a new field in which rivals are hustling along competing therapies, hoping to cash in on one of the biggest unmet medical needs in the business.
Lilly will be first up with new Phase III data on solanezumab in a matter of weeks. Merck will follow in July. Sometime over the next year, we’ll be able to understand much better just what role amyloid beta plays in Alzheimer’s. And if anyone scores pay dirt data, the payoff will potentially be worth billions a year from a new drug franchise. Losers will be relegated to a growing cemetery of failed programs.
You can also try a Google Site Search
Separate names with a comma.